Mimedx Group Files 8-K for Regulation FD Disclosure

TL;DR

MDXG filed an 8-K for a Reg FD disclosure on 3/27/24. No new material info in the filing itself.

AI Summary

Mimedx Group, Inc. filed an 8-K on March 27, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or new material events beyond the disclosure itself. The company's principal executive offices are located at 1775 West Oak Commons Court, NE, Marietta, GA 30062.

Why It Matters

This filing indicates Mimedx Group is making a public disclosure under Regulation FD, ensuring all investors receive the same material information simultaneously. It does not, however, reveal the specific content of that disclosure.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure under Regulation FD and does not contain new financial information or significant operational updates that would immediately impact risk.

Key Players & Entities

• MIMEDX GROUP, INC. (company) — Registrant
• March 27, 2024 (date) — Date of Report
• 1775 West Oak Commons Ct., NE, Marietta GA 30062 (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share MDXG The Nasdaq Sto

Filing Documents

• mdxg-20240327.htm (8-K) — 25KB
• axiofillrfdpressreleasealt.htm (EX-99) — 12KB
• image_0.jpg (GRAPHIC) — 17KB
• 0001376339-24-000026.txt ( ) — 187KB
• mdxg-20240327.xsd (EX-101.SCH) — 2KB
• mdxg-20240327_lab.xml (EX-101.LAB) — 22KB
• mdxg-20240327_pre.xml (EX-101.PRE) — 13KB
• mdxg-20240327_htm.xml (XML) — 3KB

01

Item 7.01 Regulation FD On March 27, 2024, MiMedx Group, Inc. (the "Company") issued a press release providing an update on its request for designation process with the U.S. Food & Drug Administration with respect to its product, Axiofill, and reiterating its financial guidance for the full year 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The information in this Current Report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release dated March 27, 2024

SIGNATURES

SIGNATURES Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MIMEDX GROUP, INC. March 27, 2024 By: /s/Doug Rice Doug Rice Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR